Search results for "PARKINSON DISEASE"

showing 10 items of 223 documents

Impact of Parkinson?s disease on the efficiency of masticatory cycles : electromyographic analysis

2019

Background This study evaluated the efficiency of masticatory cycles by means of the linear envelope of the electromyographic signal of the masseter and temporalis muscles in individuals with Parkinson’s disease. Material and Methods Twenty-four individuals were assigned into two groups: with Parkinson’s disease, average ± SD 66.1 ± 3.3 years (n = 12) and without the disease, average ± SD: 65.8 ± 3.0 years (n = 12). The MyoSystem-I P84 electromyograph was used to analyze the activity of masticatory cycles through the linear envelope integral in habitual mastication of peanuts and raisins and non-habitual mastication of Parafilm M®. Results There was statistically significant difference (P ≤…

Parkinson's diseaseTemporal MuscleElectromyographyTemporal muscleMasseter muscle03 medical and health sciences0302 clinical medicinemedicineHumansGeneral DentistryMasticationOrthodonticsOral Medicine and Pathologymedicine.diagnostic_testElectromyographic analysisbusiness.industryElectromyographyMasseter MuscleResearchParkinson Disease030206 dentistryRight masseter muscle:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMasticatory forceOtorhinolaryngologyMASTIGAÇÃOUNESCO::CIENCIAS MÉDICASMasticationSurgerybusiness
researchProduct

Pisa syndrome after rasagiline therapy in a patient with Parkinson’s disease

2015

Dear Editor, We have read with interest comments by Solla et al. [1] regarding our Letter to the Editor published in NeurologicalSciences titled ‘‘Insidious onset of Pisa Syndrome afterrasagiline therapy in a patient with Parkinson’s Disease’’[2]. We thank the authors for their interest in our paper, but we think it is necessary to make some clarifications regarding the temporal relationship between the onset of Pisa Syndrome (PS) and rasagiline therapy. PS occurred in fact after and not before rasagiline treatment as stated by Solla et al. In particular, PS occurred after a time interval of 6–12 months and anyway after rasagiline was added to patient’s therapy. This long time interval is o…

Pediatricsmedicine.medical_specialtyParkinson's diseaseNeurologyParkinson's diseaseDermatologyAntiparkinson Agentschemistry.chemical_compoundDopaminemedicineHumansMonoamine Oxidase Type BDystoniaRasagilineAntiparkinsonian drugsbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasePsychiatry and Mental healthDystoniaPisa syndromechemistryAntiparkinson AgentsIndansFemaleNeurology (clinical)businessmedicine.drug
researchProduct

Influence of Drugs on Mild Cognitive Impairment in Parkinson’s Disease: Evidence from the PACOS Study

2022

Background: Polytherapy and the anticholinergic activity of several drugs negatively influence cognition in the elderly. However, little is known on the effect on Mild Cognitive Impairment (MCI) in Parkinson’s Disease (PD). Methods: Patients with PD belonging to the baseline PACOS cohort with full pharmacological data, have been included in this study. MCI diagnosis was made according to the MDS level II criteria. Polytherapy was defined as patients assuming ≥6 drugs. Anticholinergic burden has been calculated using the Anticholinergic Drug Scale (ADS). Molecules have been classified according to the ATC classification. Association with MCI has been assessed with a multivariate logistic re…

PharmacologyParkinson DiseaseGeneral MedicineMiddle AgedNeuropsychological TestspolytherapydrugsCholinergic Antagonistsanticholinergic burdenPsychiatry and Mental healthmild cognitive impairmentNeurologyParkinson’s diseaseHumansSettore MED/26 - NeurologiaCognitive DysfunctionPharmacology (medical)Neurology (clinical)polypharmacyAgedCurrent Neuropharmacology
researchProduct

Nuclear Translocation of Nuclear Transcription Factor-κB by α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors Leads to Transcription of …

2003

We describe a new molecular mechanism of cell death by excitotoxicity mediated through nuclear transcription factor κB (NFκB) in rat embryonic cultures of dopaminergic neurons. Treatment of mesencephalic cultures with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) resulted in a number of changes that occurred selectively in dopaminergic neurons, including persistent elevation in intracellular Ca2+ monitored with Fura-2, and a significant increase in intramitochondrial oxidation of dihydrorhodamine 123, probably associated with transient increase of mitochondrial permeability, cytochrome c release, nuclear translocation of NFκB, and transcriptional activation of the oncogenep53.…

Programmed cell deathCell Membrane PermeabilityTime FactorsCIENCIAS MÉDICAS Y DE LA SALUDTranscription GeneticNeuriteActive Transport Cell NucleusInmunologíaExcitotoxicitymedicine.disease_causeCELL DEATHReceptors DopamineRats Sprague-DawleymedicineAnimalsReceptors AMPAalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidTranscription factorPARKINSON DISEASECaspaseNeuronsPharmacologyCell DeathNUCLEAR TRANSCRIPTIONbiologyDopaminergicNF-kappa BNFKB1Molecular biologyMitochondriaRatsCell biologyMedicina Básicabiology.proteinMolecular MedicineCalciumFemaleTumor Suppressor Protein p53Signal transductionMolecular Pharmacology
researchProduct

Lipids Nutrients in Parkinson and Alzheimer’s Diseases: Cell Death and Cytoprotection

2020

Neurodegenerative diseases, particularly Parkinson’s and Alzheimer’s, have common features: protein accumulation, cell death with mitochondrial involvement and oxidative stress. Patients are treated to cure the symptoms, but the treatments do not target the causes; so, the disease is not stopped. It is interesting to look at the side of nutrition which could help prevent the first signs of the disease or slow its progression in addition to existing therapeutic strategies. Lipids, whether in the form of vegetable or animal oils or in the form of fatty acids, could be incorporated into diets with the aim of preventing neurodegenerative diseases. These different lipids can inhibit the cytotoxi…

Programmed cell deathParkinson's diseaseInflammationReviewDiseasePharmacologyMitochondrionmedicine.disease_causelipids nutrientsCatalysislcsh:ChemistryInorganic ChemistrysynucleinFish OilsAlzheimer DiseaseHumansPlant OilsMedicinePhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopybusiness.industryFatty AcidsOrganic ChemistryapoptosisamyloidParkinson DiseaseNutrientsGeneral Medicinemedicine.diseaseLipidsCytoprotectionComputer Science ApplicationsmitochondriaOxidative Stresslcsh:Biology (General)lcsh:QD1-999CytoprotectionParkinson’s diseaseSynucleinTaumedicine.symptombusinessAlzheimer’s diseaseOxidative stressInternational Journal of Molecular Sciences
researchProduct

A high-throughput chemical screen in DJ-1β mutant flies identifies zaprinast as a potential Parkinson's disease treatment

2021

AbstractDopamine replacement represents the standard therapy for Parkinson’s disease (PD), a common, chronic, and incurable neurological disorder; however, this approach only treats the symptoms of this devastating disease. In the search for novel disease-modifying therapies that target other relevant molecular and cellular mechanisms, Drosophila has emerged as a valuable tool to study neurodegenerative diseases due to the presence of a complex central nervous system, the blood–brain barrier, and a similar neurotransmitter profile to humans. Human PD-related genes also display conservation in flies; DJ-1β is the fly ortholog of DJ-1, a gene for which mutations prompt early-onset recessive P…

Programmed cell deathParkinson's diseasePurinonesSistema nerviós central MalaltiesMutantProtein Deglycase DJ-1PharmacologyBiologymedicine.disease_causechemistry.chemical_compoundNeurologiaDopaminemedicineAnimalsPharmacology (medical)GPR35 agonistPharmacologyHigh-throughput screeningPhosphodiesteraseParkinson Diseasemedicine.diseaseOxidative StresschemistryParkinson’s diseaseDrosophilaOriginal ArticleZaprinastNeurology (clinical)Phosphodiesterase inhibitorZaprinastGPR35Oxidative stressmedicine.drug
researchProduct

Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale

2020

Neurodegenerative diseases such as Alzheimer&rsquo

Proteomicsamyotrophic lateral sclerosisParkinson's diseaseDatabases FactualProteomeDiseaseComputational biologyBiologyPolymorphism Single NucleotideArticleTranscriptomeImmune systemHuntington's diseaseAlzheimer DiseasemedicineHumansbiochemistryAmyotrophic lateral sclerosislcsh:QH301-705.5GeneAlzheimer’s disease ; multi-omics ; neurodegeneration ; Huntington’s disease ; Parkinson’s disease ; amyotrophic lateral sclerosisNeurodegenerationneurodegenerationNeurodegenerative DiseasesParkinson DiseaseGenomicsGeneral Medicinemulti-omicsmedicine.diseaseImmunity HumoralGene OntologyHuntington Diseaselcsh:Biology (General)Parkinson’s diseaseTranscriptomeAlzheimer’s diseaseGenome-Wide Association StudyHuntington’s disease
researchProduct

Effect of foot health and quality of life in patients with Parkinson disease: A prospective case-control investigation.

2022

Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG [Abstract] Background Parkinson's disease (PD) is a common neurodegenerative disorder, characterised by the presence of motor disturbances. Therefore, it can be related to musculoskeletal and orthopaedic problems, particularly in the foot status, that are linked to a negative effect on overall health, mobility and social function. Objective The aim was to analyse the impact of foot health and quality of life in patients with Parkinson's disease and people without Parkinson's disease, with normalised reference scores, in the light of the values recorded with regard to foot health status and overall health. Material an…

Quality of lifeMalemedicine.medical_specialtyPsychometricsPsicometríasCalidad de vidaHealth StatusNeuronesFoot deformitiesDermatologyDiseasePathology and Forensic MedicineQuality of lifeFoot diseasesFoot disordersStatistical significanceSurveys and QuestionnairesMedicineHumansIn patientDeformidades del pieEnfermedades del pieMeasurement/psychometricsbusiness.industryNeurodegenerative DiseasesParkinson DiseaseHealth qualityFoot health status questionnaireExtremitatsCase-Control StudiesFoot painMann–Whitney U testPhysical therapyMalaltiesQuality of LifeFemalebusinessFoot (unit)Dolor en el pieJournal of tissue viability
researchProduct

The Implications Of The Foot Health Status In Parkinson Patients : A Case-Control Study

2022

Parkinson's disease (PD) is a neurodegenerative disorder that affects bothhealth of the feet, as to gait patterns. This study aimed to find out about footproblems and their impact on self-perceived quality of life and related to foothealth in Parkinson's patients compared to a group of healthy subjects and tomeasure it with Spanish Podiatry Health Questionnaire (PHQ-S). It is about acase–control study in a sample of Parkinson's patients n=62, healthy controlsn=62. The PHQ-S was reported, it describes perception the subject has ineach of podiatric 6 dimensions consulted, assessing appreciation of health sta-tus of interviewee's feet and a self-rated the foot health score on the visual ana-lo…

Quality of lifePHQ-SFootHealth StatusParkinson's diseasePiesParkinson DiseaseDermatologyExtremitatsCase-Control StudiesFoot painQuality of LifeHumansSurgerySistema nerviós MalaltiesSpanish podiatry health questionnaireParkinson's diseaseFoot health statusSpanish podiatryhealth questionnaire
researchProduct

Early DEtection of wEaring off in Parkinson disease: The DEEP study

2014

Assessing the frequency of Wearing-Off (WO) in Parkinson's disease (PD) patients, and its impact on Quality of Life (QoL). METHODS: Consecutive ambulatory patients, who were on dopaminergic treatment for ≥ 1 year, were included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-question Wearing-Off Questionnaire (WOQ-19); WO was defined for scores ≥ 2. QoL was evaluated by the 8-item Parkinson's Disease Questionnaire (PDQ-8). RESULTS: 617 subjects were included, with a mean anti-Parkinson treatment duration of 6.6 ± 4.6 years, 87.2% were on lev…

QuestionnairesAdultMaleQuality of lifeLevodopamedicine.medical_specialtyPediatricsParkinson's diseaseTreatment durationParkinson's diseaseEarly detectionDiseaseLevodopaAntiparkinson AgentsQuality of lifeSurveys and Questionnairesmedicine80 and overHumansWearing-offAgedAged 80 and overParkinson's disease; Quality of life; Wearing-off; Wearing-off questionnairebusiness.industryParkinson DiseaseParkinson's disease; quality of life; wearing-off; wearing-off questionnaireMiddle Agedmedicine.diseaseLevodopa; Questionnaires; Parkinson's disease; Humans; Wearing-off; Quality of Life; Aged; Antiparkinson Agents; Cross-Sectional Studies; Wearing-off questionnaire; Parkinson Disease; Aged 80 and over; Adult; Middle Aged; Male; Female; Quality of lifeCross-Sectional StudiesNeurologyAmbulatoryPhysical therapyWearing-off questionnaireObservational studyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and Gerontologybusinessmedicine.drug
researchProduct